Indegene and DrugLogic announced a joint offering for pharmaceutical companies and healthcare organisations that would combine the extensive medical expertise of Indegene with the sophisticated Big-Data analysis capabilities of DrugLogic’s Qscan. This knowledge and expertise-based offering combines sophisticated evidence-based statistical results, with experience-based physician monitoring, to help decipher a drug’s clinical behaviour and detect signals related to its safety and interactions with other factors.
“Drug monitoring requires the integration of medical review coupled with sophisticated signalling and analytic systems,” said Dr Sheila Weiss, Chief Science Officer, DrugLogic. “By joining together we can rapidly deploy expert teams with immediate access to data and the analytic capabilities that drug safety requires.”
The joint solution draws synergistically upon the expertise and experience of Indegene’s team of 400+ in-house physicians and the 14+ years of application legacy of Drug Logic’s Qscan. The Indegene-DrugLogic team will offer the best of both approaches during drug discovery, through clinical trials, and post-launch. The team will provide speedy and efficient pharmacovigilance-based on many years of experience, and models to address challenging questions.
The solution will use the analytical capabilities of DrugLogic’s Qscan, an application that has been used with over 12 different databases and billions of records and extensive knowledge and expertise of Indegene’s TrialPedia platform, the most comprehensive clinical trial analytics platform with over 200,000 trials across 200+ clinical indications. The team will adapt the best data from adverse events, claims, medical records and prescription monitoring programmes that are both publically and privately available. “By putting massive amounts of data and insightful statistics in the hands of clinical experts, we will quickly, accurately, and efficiently shorten the time to understand and react to a drug’s behaviour and safety profile,” said Dr Rajesh Nair, President, Indegene.
DrugLogic’s Qscan is a platform that has been applied to several different types of databases. These include the FAERS, VAERS, and WHO databases. It has also been applied to larger medical record and claims databases, such as Medicare, Medicaid, private, and de-identified medical data.
Victor Gogolak, Founder and President, DrugLogic’s stated, “With not just a few, but a deep bench of hundreds of trained physicians, the power of analytics can be used with speed and confidence. Without the interpretive experience, statistics can be bewildering, or even misleading. With just one database, there is danger of systematic biases that can be mitigated by viewing drug behaviour from multiple angles.”
“Indegene’s collaboration with DrugLogic is testament to our philosophy of continually combining scientific expertise with innovative technology to solve pressing challenges in the pharma and healthcare industry. We believe our existing and future clients will benefit tremendously from this approach,” Nair summarised.
EP News Bureau– Mumbai